Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea

Yonsei Medical Journal

Volumn 48, Issue 5, 2007, Pages 779-786

  Lee, Jin Sol ^a   Shin, Jong Hee ^a   Lee, Kyungwon ^b   Kim, Mi Na ^c   Shia, Bo Moon ^d   Uh, Young ^e   Lee, Wee Gyo ^f   Lee, Hye Soo ^g   Chang, Chulhun L ^h   Kim, Soo Hyun ^a   Shin, Myung Geun ^a   Suh, Soon Pal ^a   Ryang, Dong Wook ^a  

^a Chonnam National University Medical School   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Yonsei University Wonju College of Medicine   (South Korea)

^f Ajou University School of Medicine   (South Korea)

^g Chonbuk National University Medical School   (South Korea)

^h Pusan National University School of Medicine   (South Korea)

Author keywords

Antifungal susceptibility; Bloodstream infections; Candida species; Trizoles

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; KOREA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SPECIES DISTRIBUTION; UNIVERSITY HOSPITAL;

EID: 36248941920     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2007.48.5.779     Document Type: Article

References (36)

1. Edmond MB, Wallace SE, McClish DK Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis Clin Infect Dis 1999;29:239-44.
2. Shin JH, Kim MN, Shin DH, Jung SI, Kim KJ, Cho D, et al. Genetic relatedness among Candida tropicalis isolates from sporadic cases of fungemia in two university hospitals in Korea. Infect Control Hosp Epidemiol 2004;25:634-40.
3. Verduyn Lunel FM, Meis JF, Voss A. Nosocomial fungal infections: candidemia. Diagn Microbiol Infect Dis 1999;34:213-20.
4. Kao AS, Brandt ME, Pruitt WR, Conn LA, Perkins BA, Stephens DS, et al. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29:1164-70.
5. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of blood-stream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001;39:3254-9.
6. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn MicrobioI Infect Dis 2004;48:153-60.
7. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 2000;44:747-51.
8. St Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, et al. Prevalence and autifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001;39:949-53.
9. Cuenca-Estrella M, Rodriguez D, Almirante B, Morgan J, Planes. AM, Almela, K et al In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from & population-based active surveillance programe, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005;55:194-9.
10. Samra Z, Yardeni M, Peled N, Bishara J, Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary medical center in Israel. Eur J Clin,Microbiol Infect Dis 2005;24:592-5.
11. da Matta DA, de Almeida LP, Machado AM, Azevedo AC, Kusano EJ, Travassos NF, et al. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Säo Paulo, Brazil, 1995-2003. Diagn. Microbiol Infect Dis 2007;18:399-404.
12. Mokaddas EM, Al-Sweih NA, Khan ZU. Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study. J Med Microbiol 2007;56:255-9.
13. Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ, et al; KONSAR group. High prevalence of ceftazidime-resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J 2006;47:634-45.
14. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 2nd ed. Approved standard M27-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2002.
15. Yi JY, Shin JH, Lee KW, Yong DE, Chae MJ, Suh SP, et al. Evaluation of spectrophotometric broth microdilution method to determine the fluconazole MIC of the Candida Species. Korean J Lab Med 2002;22:253-9.
16. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. Quantitation of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J Clin Microbiol 1999;37:3332-7.
17. Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819-26.
18. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, et al. Practice guidelines for the t reatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis 2000;30:662-78.
19. Voss A, Kluytmans JA, Koeleman JG, Spanjaard L, Vandenbroucke-Grauls CM, Verbrugh HA, et al. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microbiol Infect Dis 1996;15:909-12.
20. Abi-Said D, Anaissie E, Uzun O, Raad L Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24:1122-8.
21. Pfaller MA, Diekema DJ. International Fungal Surveillance Participant Group. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin Microbiol. Infect 2004;10:11-23.
22. Krcméry V Jr, Kovacicová G. Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study.group. Diagn Microbiol Infect Dis 2000;36:7-11.
23. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004;53:283-9.
24. Collin B, Clancy CJ, Nguyen MH. Antifungal resistance in non-albicans Candida species. Drug Resist Update 1999;2:9-14.
25. Pfaller MA, Jones RN, Doern GV, Sader HS, Hollis RJ, Messer SA. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group. J Clin Microbiol 1998;36:1886-9.
26. Shin JH, Shin DH, Song JW, Kee SJ, Suh SP, Ryang DW. Electrophoretic karyotype analysis of sequential Candida parapsilosis isolates from patients with persistent or recurrent fungemia. J Clin Microbiol 2001;39:1258-63.
27. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, et al. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 2002;40:1244-8.
28. Levin AS, Costa SF, Mussi NS, Basso M, Sinto SI, Machado C, et al. Candida parapsilosis fungemia associated with implantable and semi-implantable central venous catheters and the hands of healthcare workers. Diagn Microbiol Infect Dis 1998;30:243-9.
29. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathogens of Epidemiologic. Diagn Microbiol Infect Dis 1998;30:121-9.
30. Pappas, PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and paediatric patients. Clin Infect Dis 2003;37:634-43.
31. Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli R, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected dusing a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005;49:668-79.
32. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM. Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin kcrobibl 2004;42:1519-27.
33. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents Against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46: 1723-7.
34. Tortorano AM, Rigoni AL, Biraghi E, Prigitano, A, Viviani MA; The FIMLIA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003;52:679-82.
35. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997;24:235-47.
36. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8.